Outcome of allogeneic hematopoietic stem-cell transplantation for adult patients with AML and 11q23/MLL rearrangement (MLL-r AML)

Leukemia

Volumn 29, Issue 12, 2015, Pages 2375-2381

  Pigneux, A ^a,b   Labopin, M ^c,d,e   Maertens, J ^f   Cordonnier, C ^g   Volin, L ^h   Socie G ⁱ   Blaise, D ^j   Craddock, C ^k   Milpied, N ^a   Bacher, U ^l   Malard, F ^c,d,e   Esteve, J ^m   Nagler, A ^c,n   Mohty, M ^c,d,e  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c HÔPITAL SAINT ANTOINE   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g HENRI MONDOR HOSPITAL   (France)

^h HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

ⁱ SAINT LOUIS HOSPITAL   (France)

^j INSTITUT PAOLI CALMETTES   (France)

^k UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^l MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^m HOSPITAL CLÍNIC   (Spain)

ⁿ SHEBA MEDICAL CENTER   (Israel)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE LYSINE METHYLTRANSFERASE; MIXED LINEAGE LEUKEMIA PROTEIN; MLL PROTEIN, HUMAN;

ADULT; AGED; ALLOTRANSPLANTATION; CHROMOSOME 11; CHROMOSOME ABERRATION; CLINICAL TRIAL; FEMALE; GENE REARRANGEMENT; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; RECURRENT DISEASE; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 11; FEMALE; GENE REARRANGEMENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELOID-LYMPHOID LEUKEMIA PROTEIN; RECURRENCE; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84951569594     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.143     Document Type: Article

References (23)

1. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453-474.
2. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010; 116: 354-365.
3. Bloomfield CD, Archer KJ, Mrozek K, Lillington DM, Kaneko Y, Head DR et al.
4. Super HJ, McCabe NR, Thirman MJ, Larson RA, Le Beau MM, Pedersen-Bjergaard J, et al. Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-Topoisomerase II. Blood 1993; 82: 3705-3711.
5. Muntean AG, Hess JL. The pathogenesis of mixed-lineage leukemia. Annu Rev Pathol 2012; 7: 283-301.
6. Meyer C, Hofmann J, Burmeister T, Groger D, Park TS, Emerenciano M, et al. The MLL recombinome of acute leukemias in 2013. Leukemia 2013; 27: 2165-2176.
7. Martin ME, Milne TA, Bloyer S, Galoian K, Shen W, Gibbs D, et al. Dimerization of MLL fusion proteins immortalizes hematopoietic cells. Cancer Cell 2003; 4: 197-207.
8. Ayton PM, Cleary ML. Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev 2003; 17: 2298-2307.
9. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322-2333.
10. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000; 96: 4075-4083.
11. Tamai H, Inokuchi K. 11q23/MLL acute leukemia: update of clinical aspects. J Clin Exp Hematop 2010; 50: 91-98.
12. Balgobind BV, Zwaan CM, Pieters R, Van den Heuvel-Eibrink MM. The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia. Leukemia 2011; 25: 1239-1248.
13. Krauter J, Wagner K, Schafer I, Marschalek R, Meyer C, Heil G, et al. Prognostic factors in adult patients up to 60 years old with acute myeloid leukemia and translocations of chromosome band 11q23: individual patient data-based metaanalysis of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 2009; 27: 3000-3006.
14. Mrozek K, Heinonen K, Lawrence D, Carroll AJ, Koduru PR, Rao KW, et al. Adult patients with de novo acute myeloid leukemia and t(9; 11)(p22; q23) have a superior outcome to patients with other translocations involving band 11q23: a cancer and leukemia group B study. Blood 1997; 90: 4532-4538.
15. Martineau M, Berger R, Lillington DM, Moorman AV, Secker-Walker LM. The t(6;11) (q27;q23) translocation in acute leukemia: a laboratory and clinical study of 30 cases. EU Concerted Action 11q23 Workshop participants. Leukemia 1998; 12: 788-791.
16. Chen Y, Kantarjian H, Pierce S, Faderl S, O'Brien S, Qiao W, et al. Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation. Leukemia 2013; 27: 836-842.
17. Blum W, Mrozek K, Ruppert AS, Carroll AJ, Rao KW, Pettenati MJ, et al. Adult de novo acute myeloid leukemia with t(6;11)(q27;q23): results from Cancer and Leukemia Group B Study 8461 and review of the literature. Cancer 2004; 101: 1420-1427.
18. Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009; 15: 1628-1633.
19. Flowers ME, Kansu E, Sullivan KM. Pathophysiology and treatment of graft-versushost disease. Hematol Oncol Clin North Am 1999; 13: 1091-1112, viii-ix.
20. Ferrant A, Labopin M, Frassoni F, Prentice HG, Cahn JY, Blaise D, et al. Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European Group for Blood and Marrow Transplantation study. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Blood 1997; 90: 2931-2938.
21. Groschel S, Schlenk RF, Engelmann J, Rockova V, Teleanu V, Kuhn MW, et al. Deregulated expression of EVI1 defines a poor prognostic subset of MLLrearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group. J Clin Oncol 2013; 31: 95-103.
22. Daigle SR, Olhava EJ, Therkelsen CA, Basavapathruni A, Jin L, Boriack-Sjodin PA, et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood 2013; 122: 1017-1025.
23. Garrido SM, Bryant E, Appelbaum FR. Allogeneic stem cell transplantation for relapsed and refractory acute myeloid leukemia patients with 11q23 abnormalities. Leuk Res 2000; 24: 481-486.